National Institute of Allergy and Infectious Diseases
NIAID Home Health & Science Research Funding Research News & Events Labs at NIAID About NIAID

HIV/AIDS
 Understanding
 Research
  Research Overview
  Basic Science
  Epidemiology
  Prevention
  Therapeutics
  Vaccines
   Introduction and Goals
   Research Activities
   Resources for Researchers
   Funding
   Meetings
   Reports and Articles
   Advisory and Working Groups
   Clinical Trials
   Considerations Papers
   Education and Outreach
  Clinical Research
  Advisory Groups and Committees
  Partners and Collaborators
  Funding Opportunities
 HIV/AIDS Clinical Trials


HIV/AIDS

Vaccine Reagent Resource

The Reagent Resource Support for AIDS Vaccine Development Program provides for procurement or production of reagents essential to AIDS vaccine development and evaluation, plus the independent performance of quality assurance testing of these reagents.

This program provides reagents, resources, and quality assurance/quality control analysis (QA/QC) in support of the DAIDS vaccine research effort including the procurement or production and distribution of working quantities of common reagents needed for immunological evaluation of the vaccinated subjects participating in DAIDS-supported clinical and preclinical trials. For example, acquiring agents required for the HIV Vaccine Trials Network (HVTN). These may include viral gene products and associated peptides, adjuvants, cytokines, virus stocks, expression vectors, monoclonal and polyclonal antibodies, and sometimes unforeseen but appropriately and timely produced reagents. These reagents are generated for evaluating vaccine safety, immunogenicity, and efficacy. In some cases, such reagents may not be commercially available and would require customized production and quality control. The independent QA/QC testing performed on the reagents supplied through this contract aims to establish standardization of assays among the laboratories supported by this contract, thus improving the reproducibility and comparability of results among DAIDS-supported vaccine research groups.

Contact:
Dr. Jon Warren
Division of AIDS, Preclinical Research and Development Branch
Phone: 301-402-0633
E-mail: jwarren@niaid.nih.gov

 

Highlights

Statement of Anthony S. Fauci, M.D., on HIV Vaccine Awareness Day —May 15, 2009

HIV Vaccine Awareness Day—May 18

See Also

  • Division of AIDS
  • Vaccine Research Center
  • HIV/AIDS Publications
  • HIV/AIDS News Releases
  • Global Research, Africa
  • Selected NIAID Science Advances, 2007-2008 (PDF)
  • Vaccines
  • NIAID Funding News

  • Highlights

    Statement of Anthony S. Fauci, M.D., on HIV Vaccine Awareness Day —May 15, 2009

    HIV Vaccine Awareness Day—May 18

    See Also

  • Division of AIDS
  • Vaccine Research Center
  • HIV/AIDS Publications
  • HIV/AIDS News Releases
  • Global Research, Africa
  • Selected NIAID Science Advances, 2007-2008 (PDF)
  • Vaccines
  • NIAID Funding News